Macquarie Group
CGEM icon

Macquarie Group’s Cullinan Oncology CGEM Stock Holding History

Macquarie Group’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,101
Closed -$14.8K – 2292
2022
Q2 		$14K Hold
1,101
– – ﹤0.01% 2388
2022
Q1 		$12 Hold
1,101
– – ﹤0.01% 2488
2021
Q4 		$17K Buy
+1,101
New +$22K ﹤0.01% 2429

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Macquarie Group's CGEM Position: Q3 2022 in Review

Macquarie Group sold out of Cullinan Oncology (CGEM) in Q3 2022, closing a stake of 1,101 shares — an estimated $14.8K sold.

Macquarie Group first reported a position in CGEM in Q4 2021 and held it in 3 quarters. The position peaked at $17K in Q4 2021. 99 funds tracked by Wall St. Rank hold CGEM as of Q3 2022.

  • Macquarie Group reported no remaining Cullinan Oncology position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 1,101 Cullinan Oncology shares in Q3 2022, an estimated $14.8K.
  • Macquarie Group first reported a position in Cullinan Oncology in Q4 2021 and held it in 3 quarters.
  • Macquarie Group's Cullinan Oncology position peaked at $17K in Q4 2021.
  • 99 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.